Fast-Track Drug Registration for Local Manufacturers: PPB Timelines and Fees Explained

A local pharmaceutical manufacturer planning a registration budget and timeline needs accurate figures from the Pharmacy and Poisons Board, not a secondhand estimate. Some of what follows is confirmed directly from PPB’s own published fee schedule. Some of it is not currently verifiable from PPB’s own materials, and this article says so plainly rather than presenting a borrowed figure as confirmed.

Three Submission Pathways at PPB

PPB’s own procedure guidance for medicines evaluation and registration describes three submission routes: the standard first-in-first-out pathway, a fast-track pathway described as full assessment and reliance, and an expedited pathway reserved for emergency or compassionate use products. A local manufacturer’s application would typically move through the standard or fast-track route depending on eligibility, with the expedited route reserved for a narrower set of circumstances. PPB’s site references a separate guideline document specifically covering fast-track review eligibility criteria, and a manufacturer should request and review that document directly from PPB before assuming their product qualifies, since the precise eligibility criteria were not accessible for direct verification here.

Registration Fees: The Confirmed Figures

PPB’s own Schedule of Fees for Regulatory Activities, issued under the Pharmacy and Poisons (Registration of Health Products and Technologies) Rules 2022 and effective from 1 January 2026, sets out a clear local-versus-imported split. A registration application for a product manufactured in Kenya costs USD 500, against USD 1,000 for a product not manufactured in Kenya. Renewal fees follow the same pattern, USD 500 for locally manufactured products against USD 1,000 for imported ones. Good Manufacturing Practice audit fees show the same structural discount and a wider gap in absolute terms: USD 1,000 per site for a local manufacturer against USD 4,000 per site for a foreign one. These figures come directly from PPB’s own published schedule and can be relied on as the current fee structure, though a manufacturer should always confirm against the live schedule at the time of application in case of interim revision.

What Could Not Be Verified: Fast-Track Timelines

PPB’s procedure page references a flow chart setting out marketing authorisation pathways and timelines, but its content was not retrievable for direct verification, and no PPB-published page or document stating explicit month-based processing targets, such as a specific number of months for local applications against imported ones, could be confirmed. A figure of three to six months for expedited local-manufacturer evaluation has circulated in press coverage attributed to PPB’s Acting CEO, but it could not be located verbatim on PPB’s own site as a published commitment. A manufacturer building a launch timeline around a specific processing period should confirm that figure directly with PPB in writing rather than rely on secondary reporting, however credible the outlet.

The Fast-Track Fee Question

PPB’s fee schedule includes a separate fast-track evaluation line item of USD 2,000, but the schedule as reviewed lists this against imported products, and it was not possible to confirm from the extracted schedule text whether a separate, discounted fast-track fee exists specifically for local manufacturers or whether local manufacturers pay the same USD 2,000 fast-track premium on top of the lower base registration fee. Given the financial significance of this distinction for a manufacturer weighing whether fast-track review is worth the additional cost, this is a figure worth confirming directly against PPB’s raw fee schedule document, or with PPB itself, before it is built into a registration budget.

The August 2026 Reforms in Context

PPB’s own site published a statement on 21 August 2026 describing reforms intended to strengthen patient protection, confirming that PPB is actively supporting thirteen new local manufacturers through GMP inspections, technical guidance, and registration support. This confirms genuine, current PPB engagement with local manufacturing capacity building, consistent with the fee-discount structure above. What that statement does not contain is any new fee figure or processing-timeline commitment; those specifics, where reported elsewhere, should be treated as secondary commentary on PPB’s direction rather than a PPB-published rule until confirmed against PPB’s own materials.

Building a Registration Budget Around Confirmed Figures

The practical approach for a local manufacturer is to build a registration budget on the figures PPB has actually published, treat the fast-track timeline and fee questions as open items to resolve directly with PPB before committing to a launch date, and revisit both once PPB’s own fast-track eligibility guideline and timeline flow chart can be obtained and reviewed in full. Budgeting the confirmed USD 500 registration fee and USD 1,000 per-site GMP audit fee for a local product, while separately confirming in writing whether the USD 2,000 fast-track line item applies on top of that base fee, avoids the common planning error of assuming a discount applies everywhere a local-manufacturer figure appears in the schedule. This distinction matters more for a manufacturer with multiple products or multiple manufacturing sites, where a fee assumption applied incorrectly across a portfolio compounds quickly.